Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 3/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21580883 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL14746081 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL30636923 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL14746082 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL23700570 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL23700653 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL23700652 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL23700568 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL20521886 | 0.91 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL20521887 | 0.91 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | O60361, ARG1, QDPR | NR1H2 124/4885USP2 3624/4885SMN1; SMN2 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.